Article

[O-methyl-\(^{11}\)C]N-(4-(4-(3-Chloro-2-methoxyphenyl)piperazin-1-yl)butyl)-1\(^H\)-indole-2-carboxamide ([\(^{11}\)C]BAK4-51) Is an Efflux Transporter Substrate and Ineffective for PET Imaging of Brain D\(_3\) Receptors in Rodents and Monkey

Jeih-San Liow \(^1\), Cheryl L. Morse \(^1\), Shuiyu Lu \(^1\), Michael Frankland \(^1\), George L. Tye \(^1\), Sami S. Zoghbi \(^1\), Robert B. Shaik \(^2\), Robert B. Innis \(^1\), Amy H. Newman \(^2\) and Victor W. Pike \(^1\)

\(^1\) Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Room B3C346, 10 Center Drive, Bethesda, MD 20892, USA; liowj@mail.nih.gov (J.-S.L.); morsec@mail.nih.gov (C.L.M.); michael.frankland@nih.gov (M.F.); george.tye@gmail.com (G.L.T.); zoghbis@mail.nih.gov (S.S.Z.); gladdingr@mail.nih.gov (R.L.G.); innisr@mail.nih.gov (R.B.I.); pikev@mail.nih.gov (V.W.P.)

\(^2\) Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, National Institutes of Health, 333 Cassell Drive, Baltimore, MD 21224, USA; aner.shaik@nih.gov (A.B.S.); anewman@intra.nida.nih.gov (A.H.N.)

* Correspondence: shuiyu.lu@mail.nih.gov; Tel.: +1-301-451-3904

Received: 26 September 2018; Accepted: 18 October 2018; Published: 23 October 2018

Abstract: Selective high-affinity antagonists for the dopamine D\(_3\) receptor (D\(_3\)R) are sought for treating substance use disorders. Positron emission tomography (PET) with an effective D\(_3\)R radioligand could be a useful tool for the development of such therapeutics by elucidating pharmacological specificity and target engagement in vivo. Currently, a D\(_3\)R-selective radioligand does not exist. The D\(_3\)R ligand, N-(4-(4-(3-chloro-2-methoxyphenyl)piperazin-1-yl)butyl)-1\(^H\)-indole-2-carboxamide (BAK4-51, \(^1\)), has attractive properties for PET radioligand development, including full antagonist activity, very high D\(_3\)R affinity, D\(_3\)R selectivity, and moderate lipophilicity. We labeled \(^1\) with the positron-emitter carbon-11 (\(t\(_{1/2}\) = 20.4 min) in the methoxy group for evaluation as a radioligand in animals with PET. However, [\(^{11}\)C]1 was found to be an avid substrate for brain efflux transporters and lacked D\(_3\)R-specific signal in rodent and monkey brain in vivo.

Keywords: dopamine D\(_3\) receptors; antagonist; radiolabeling; PET; efflux transporter substrate

1. Introduction

The dopamine D\(_3\) receptor (D\(_3\)R), a member of the dopamine D\(_2\)-like receptor family, is highly localized in neurocircuits that play an important role in emotional and cognitive functions [1–5]. Aberrant D\(_3\)R signaling has been linked to multiple neurological and psychiatric conditions, such as Parkinson’s disease [6], schizophrenia [6], behavioral sensitization [7], depression [8], and substance use disorders (SUD) [9–11].

Positron emission tomography (PET) can provide quantitative information on the distribution of many brain proteins of biomedical interest (e.g., neureceptors) in healthy and diseased states of living subjects through the measurement of selective radioligand distribution. PET can also assist in the development and evaluation of potential therapeutics by, for example, providing information on target engagement under prescribed trial dosing regimens [12–16]. The availability of effective radioligands is key to exploiting the full potential utility of PET in drug development. In an in-depth
review [17], Mach and Luedtke recently discussed the gap between the need for D₃R-specific PET radioligands and the challenges encountered in their development. An enormous medicinal chemistry effort has led to the discovery of many highly selective D₃R ligands but no effective PET radioligand for D₃R has emerged. Two key hurdles to PET radioligand development are (a) how to design a ligand that is able to differentiate between D₂R and D₃R, which share ~80% homology within ligand binding domains [18], and (b) how to overcome the coexistence of D₂R and D₃R in several brain regions, such as the D₃R-rich striatum where the density of D₂R exceeds [19] the density of D₃R by ratios that are reported to be at least 2:1 [20–22], dependent on measurement methodology. A few high-affinity and selective D₃R ligands have been evaluated as candidate D₃R PET radioligands ([¹¹C]PHNO [21,23]; [¹¹C]RGH1756 [24]; [¹⁸F]FTP [25]; [¹¹C]FAUC 346 [26] and [¹¹C]Naphthamide 1 [27]) (Chart 1), but none has so far proved wholly effective [28]. Various factors, including insufficiently high D₃R affinity or the possibility that D₃R are highly occupied by endogenous dopamine in vivo [21], may be responsible for the lack of efficacy in these radioligands. [¹¹C]PHNO has been widely used for PET studies of D₃R in human subjects but suffers from contamination of the PET signal in many brain regions by a high proportion of signal from D₂R [29]. This lack of selectivity exacerbates the difficulty of brain D₃R quantification.

![Chart 1. Structures of some former candidate D₃R PET radioligands and [¹¹C]I.](image)

In our search for high-affinity dopamine D₃R-selective antagonists for treating SUD, we have discovered several D₃R-selective ligands that may be suitable for development as PET radioligands [30]. To further understand the molecular basis for pharmacological specificity towards the D₃R and in particular, to provide a biomarker for receptor engagement in our efforts toward pharmacotherapeutic development, we chose one of the highest affinity (hD₃R Kᵢ, 0.4 nM) and D₃R-selective (hD₂R Kᵢ, 53 nM) full antagonists in this series, namely N-(4-(4-(3-chloro-2-methoxyphenyl)piperazin-1-yl)butyl)-1H-indole-2-carboxamide (BAK4-51; 1) [30] as a prospective PET radioligand. We report the synthesis of [¹¹C]1 (Chart 1) and its evaluation with PET in rodents and monkey.
2. Results and Discussion

2.1. Lead Compound Selection

Compound 1 was recently identified as a lead D₃R-selective antagonist [30]. For this chemotype, the 4-phenylpiperazine moiety binds to the highly homologous D₃R/D₃R orthosteric binding site, whereas the indole-2-carboxamide terminus binds in a secondary binding pocket that differs topographically between D₂R and D₃R [31–33]. Incorporation of a 2-OCH₃, 3-Cl-substituted phenyl ring and a 4-carbon linker resulted in a high affinity ligand at D₂R (D₂R Kᵢ = 0.39 ± 0.04 nM, D₃R Kᵢ = 53.0 ± 6.2) with 13-fold selectivity for D₂R over D₃R [30]. Functional assay and off target binding assay data showed that 1 is a full antagonist (IC₅₀ = 40 nM in the mitogenesis assay in hD₃R transfected CHO cells) and exhibited relatively low affinities toward other neuroreceptors compared to D₃R, as demonstrated by the Kᵢ values for D₁ (2290 ± 340 nM), D₄ (300 ± 100 nM), 5-HT₁₅ (92.3 ± 8.0 nM), 5-HT₂A (19.7 ± 1.4 nM) and 5-HT₂C (51 ± 11 nM) receptors. cLogD for compound 1 is 2.19 and the CNS MPO score is >3, which are within the ranges deemed suitable for penetration of the blood-brain barrier (BBB) [34–36]. The 2-OCH₃ substituent provides a suitable site for labeling with carbon-11.

2.2. Radiolabeling of [¹¹C]I

O-Demethylation of 1 [30] with BBr₃ gave the phenol 2 in 65% yield for use as a precursor for radiolabeling. Treatment of 2 with [¹¹C]iodomethane in the presence of a weak base, n-Bu₄NOH, in DMF at room temperature for 5 min with the ‘loop method’ [37] readily gave [¹¹C]I (Figure 1), which was purified with reversed phase HPLC and formulated for intravenous injection. The yield of formulated [¹¹C]I was 8 ± 3% (n = 8) from cyclotron-produced [¹¹C]carbon dioxide, the radiochemical purity greater than 99%, and the molar activity (Aₘ) 251 ± 83 GBq/μmol (n = 8) at the end of synthesis and formulation (about 45 min from the start of radiosynthesis). The high Aₘ value shows that the starting desmethyl precursor (2) was obtained free of any significant amount of contamination with residual carrier (1). Reversed phase HPLC of the reaction mixture revealed two radioactive byproducts with shorter retention time (tᵣ ≤ 7 min) than [¹¹C]I (tᵣ = 10–11 min), indicating possible [¹¹C]-methylation competition at the amide and/or indole nitrogens. However, since [¹¹C]I was well separated from these byproducts and its desmethyl precursor 2 (tᵣ = 6 min), no further development of the separation was undertaken. [¹¹C]I was highly stable in saline containing ethanol (10% v/v) for up to 2.5 h because HPLC analysis of the formulated radioligand solution showed that radiochemical purity decreased only slightly from 99% to 96%.

![Figure 1. Radiosynthesis of [¹¹C]I from its desmethyl precursor 2 and [¹¹C]iodomethane. Precursor 2 was prepared from compound 1 by treatment with BBr₃.](image)

2.3. LogD₇.₄, Stability and Plasma Free Fraction for [¹¹C]I

The logD₇.₄ of [¹¹C]I at room temperature was found to be 3.33 ± 0.13 (n = 6), and somewhat higher than calculated. However, this value is still within the lipophilicity range that is regarded as desirable for PET radioligands targeting brain [38]. Human plasma free fraction (fₚ) was low
Although a higher and more accurately measurable $f_p$ value would be desirable for PET studies, low $f_p$ does not strictly preclude PET radioligand utility, as shown with $[^{11}C]$MePPEP ($f_p = 0.05 \pm 0.01\%$) [39]. $[^{11}C]1$ demonstrated good stability for at least 30 min at 37 °C in rat whole blood (100%), human (99.3%), and rat plasma (98.8%), and in rat brain (99.4%), monkey brain (100%), and human brain (99.8%) homogenates. The cellular uptake in rat whole blood in vitro at 37 °C was 55.2 ± 1.1 % ($n = 3$). High cell uptake could be one of the many factors that counter the ability of a radioligand to readily enter brain. Ex vivo evaluation showed that in rat plasma there were at least five radiometabolites with much less lipophilicity than $[^{11}C]1$, based on shorter reversed phase HPLC retention times. Under baseline conditions 76% of the radioactivity in the plasma at 30 min after administration of $[^{11}C]1$ was unchanged radioligand (Table 1). In some experiments tariquidar [40] was pre-administered at doses in the range 4 to 16 mg i.v. to inhibit the action of the efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) at the BBB [41,42]. This treatment had little effect on the radiometabolite profile in plasma as 69% of the radioactivity in the plasma at 30 min after administration of $[^{11}C]1$ was unchanged radioligand (Table 1). Nearly all radioactivity measured in brain tissues was unmetabolized $[^{11}C]1$ (Table 1).

### Table 1. Unmetabolized $[^{11}C]1$ in rat plasma and brain tissues at 30 min after i.v. injection.

| Tissue    | Unmetabolized $[^{11}C]1$ (%) |
|-----------|--------------------------------|
|           | Baseline ($n = 1$) | Tariquidar-Treated ($n = 1$) |
| Plasma    | 76.1               | 68.9                        |
| Cortex    | 99.0               | 98.7                        |
| Cerebellum| 98.8               | 98.8                        |
| Striatum  | 99.3               | 98.8                        |

2.4. $[^{11}C]1$ Is a Brain Efflux Transporter Substrate in Rat, Mouse, and Monkey

Brain tissue radioactivity concentrations (SUV) in rats under baseline and tariquidar-treated (16 mg/kg, i.v.) conditions, measured ex vivo at 30 min after intravenous injection of $[^{11}C]1$, are summarized in Table 2. Whole blood and plasma concentrations of $[^{11}C]1$ were similar in tariquidar-treated and untreated rats. Whole blood and plasma concentrations were the same before and after tariquidar treatment. In tariquidar-treated rats, the concentrations of $[^{11}C]1$ in rat brain tissue were markedly higher than in untreated rats by 2.4–2.6 fold, indicating a significant action of the efflux transporter, P-gp, on $[^{11}C]1$ brain uptake under baseline conditions. Ratios of $[^{11}C]1$ in cortex or striatum to cerebellum (1.1–1.2) were similar in tariquidar-treated and untreated rats, indicating little or no preference for $[^{11}C]1$ to bind to D$_3$R-rich non-cerebellar regions.

### Table 2. Rat brain tissue concentrations (SUV) of $[^{11}C]1$ under baseline and tariquidar-treated conditions measured ex vivo 30 min after intravenous injection of radioligand.

| Tissue    | $[^{11}C]1$ Concentration (SUV) |
|-----------|--------------------------------|
|           | Baseline ($n = 1$) | Tariquidar-Treated ($n = 1$) |
| Plasma    | 0.06               | 0.04                        |
| Whole Blood| 0.09               | 0.07                        |
| Cerebellum| 1.20               | 2.84                        |
| Cortex    | 1.33               | 3.49                        |
| Striatum  | 1.36               | 3.53                        |

$^1$ SUV = standardized uptake value.

PET imaging of rats before and after tariquidar treatment (16 mg/kg, i.v.) provided similar findings to those obtained by ex vivo studies. Peak brain radioactivity concentration increased from 1.1 to 3.4 SUV (Figure 2a) after P-gp inhibition. The striatum to cerebellum radioactivity concentration ratio ($\approx$1) was unchanged when P-gp was inhibited (time-activity curves not shown). Moreover, the
relatively high uptake of $[^{11}\text{C}]$I in cerebellum does not accord with the low density of D$_3$R in cerebellum observed in vitro [20–22]. These results may indicate some off-target and/or high non-specific binding.

![Graph](image1)

**Figure 2.** (a) Whole brain PET TACs for $[^{11}\text{C}]$I in rats under baseline ($n=3$) and tariquidar-treated ($n=2$) condition, and in wild type ($n=2$) mice. Data are mean ± SD for $n=3$ and mean ± range for $n=2$. One-sided error bars represent standard deviation.

To further explore the action of efflux transporters on the brain uptake of $[^{11}\text{C}]$I, and to test whether BCRP may act on $[^{11}\text{C}]$I, PET experiments were performed in wild type and P-gp/BCRP double knock-out (KO) mice. Uptake of $[^{11}\text{C}]$I in the brain was higher in the P-gp/BCRP KO mice than in wild type mice (peak uptake 1.6 vs. 0.7 SUV) (Figure 2b). These results clearly demonstrated that $[^{11}\text{C}]$I is an avid brain efflux transporter substrate in rodents. Many formerly tested candidate radioligands for D$_3$R have strong structural similarity to $[^{11}\text{C}]$I (Chart 1) but it is unreported whether these radioligands, some of which show low brain uptake, are also substrates for brain efflux transporters.

To test whether any of the uptake of $[^{11}\text{C}]$I in rat brain represented D$_3$R-specific binding, experiments were performed with pharmacological challenge from another high-affinity selective D$_3$R ligand, BP897 (D$_3$R $K_i = 0.92$ nM) which has been used to displace $[^{11}\text{C}]$P-NOH in vivo [43]. Two rats were each treated with tariquidar (16 mg/kg, i.v.) 15 min before injection of $[^{11}\text{C}]$I. One rat was also treated with BP897 (0.5 mg/kg, i.v.) at 10 min before radioligand injection, and the other with BP897 (0.5 mg/kg, i.v.) at 15 min after radioligand injection. No major changes in the shapes of TACs were observed as a result of BP897 administration (Figure 3a).

![Graph](image2)

**Figure 3.** (a) PET TACs after administration of $[^{11}\text{C}]$I to rats (i) at baseline ($\bigcirc$, $n=1$), (ii) after pretreatment with tariquidar (16 mg/kg, i.v.) plus BP897 (0.5 mg/kg, i.v.) ($\bigotimes$, $n=1$), and (iii) after pretreatment with tariquidar (16 mg/kg, i.v.), and then with BP897 (0.5 mg/kg, i.v.) at 15 min after $[^{11}\text{C}]$I ($\bigtriangleup$, $n=1$). (b) PET TACs after administration of $[^{11}\text{C}]$I to rats (i) at baseline ($\bigcirc$, $n=1$), (ii) after pretreatment with tariquidar (16 mg/kg, i.v.) plus spiperone (1.0 mg/kg, i.v.) ($\bigotimes$, $n=1$), and (iii) after pretreatment with tariquidar (16 mg/kg, i.v.), and then with spiperone (1.5 mg/kg, i.v.) at 15 min after $[^{11}\text{C}]$I ($\bigtriangleup$, $n=1$).
The D_3R subtype shares a substantial portion of amino acid sequence and tissue distribution with the D_2R subtype but is much less abundant and has more restricted tissue localization than the D_2R subtype [18,32]. We suspected that some of the rat brain radioactivity uptake might be bound to D_2R. To test this possibility, pre-blocking and displacement experiments were also carried out using a selective D_2-like receptor ligand, spiperone (D_2R, K_i = 0.2 nM) [44–46]. Two rats were each treated with tariquidar (16 mg/kg, i.v.) at 15 min before injection of [^{11}C]I. One was treated with spiperone (1.0 mg/kg, i.v.) at 10 min before radioligand injection and the other with spiperone (1.0 mg/kg, i.v.) at 15 min after radioligand injection. No obvious changes in the TACs were observed after administration of spiperone (Figure 3b). The striatum to cerebellum ratio changed slightly from 1.0 to 1.3 from 20 min to the end of scan sessions. However, these ratios were indistinguishable between baseline, preblocking, and displacement conditions. Therefore, we found no clear evidence for off-target binding of [^{11}C]I to D_2R in vivo.

In monkey PET experiments, the peak whole brain radioactivity uptake after intravenous administration of [^{11}C]I was moderate (2–3 SUV) and early at baseline. Peak uptakes of radioactivity in putamen, frontal cortex, thalamus and occipital cortex were somewhat higher than in cerebellum (Figure 4a). Many other brain regions not shown in Figure 4a gave TACs that resembled those for the rodent and monkey. Peak radioactivity concentrations declined at a very slow rate from all brain regions over the 90-min scan period. The ratio of radioactivity in putamen to that in cerebellum was 1.4 at both 9 and 35 min after injection, thereby indicating low or absent D_3R specific binding.

![Figure 4](image-url)  
**Figure 4.** Time-activity curves of in monkey administered [^{11}C]I under baseline (a) and tariquidar-pretreated conditions (b).

In the same monkey pretreated with tariquidar, peak brain uptake of [^{11}C]I increased in all regions to between 3 and 4 SUV (Figure 4b). Areas-under the curve (AUC) between 0 and 90 min were higher than at baseline, ranging from ~20% higher in occipital cortex to 70% higher in putamen. Therefore, on the assumption that input of radioligand into brain was not increased appreciably under tariquidar treatment, [^{11}C]I appears to be a substrate for P-gp in monkey, as in rodents. The ratio of radioactivity in putamen to cerebellum increased to 2.0 at 7 min and to 1.7 and 35 min, respectively, compared to about 1.4 at baseline. PET images (Figure 5) clearly showed high radioactivity uptake in striatum. However, radioactivity washout was faster in putamen than in other regions. The high radioactivity uptake in D_3R and D_2R poor cerebellum also indicates there is appreciable non-specific binding or off-target binding. Because of the clear efflux transporter substrate behavior of [^{11}C]I across species, and the non-displaceable nature of the radioactivity in rat brain, we did not pursue further drug challenge experiments in monkey to elucidate the nature of the higher uptake of radioactivity in striatum than in cerebellum. Taken altogether the data show [^{11}C]I is ineffective as a PET D_3R in rodent and monkey.
The common features of D2R and D3R receptors add substantial challenges to the development of D3R-selective therapeutics and to the investigation of molecular mechanisms [17] involving D3Rs in the human brain [47,48]. Considering the \( B_{\text{max}} \) differences of D2R and D3R in monkey [21], rat, and human [49], a successful PET radioligand may require D3R over D2R selectivity of >500. Although this selectivity ratio has been achieved for a few compounds [48,50], to our knowledge, so far none of these molecules has been developed as a PET radioligand. Of note, Mach et al. also demonstrated the effect of endogenous dopamine on the uptake of the D3R preferring radioligand, \([^{18}F]FTP \) [25]. Pretreatment with lorazepam (1 mg/kg, i.v.) at 30 min before radioligand reduced endogenous dopamine activity before tracer injection and increased \([^{18}F]FTP \) uptake in the caudate, putamen, and thalamus. Hence, it may be necessary to consider reducing endogenous dopamine competition in PET studies especially with isoflurane-anesthetized animal subjects. In this regard, Sóvágó et al. used reserpine in an effort to reduce synaptic dopamine levels in their evaluation of \([^{13}C]RGH1756 \) in cynomolgus monkey [51], but this treatment resulted in no improvement of radioligand performance because D3R-specific binding was still not detected.

3. Materials and Methods

3.1. Synthesis of \( N-(4-(4-(3\text{-Chloro}-2\text{-hydroxyphenyl})\text{piperazin}-1\text{-y1})\text{butyl})\text{-1H-indole-2-carboxamide (2)} \)

\( N-(4-(4-(3\text{-Chloro}-2\text{-methoxyphenyl})\text{piperazin}-1\text{-y1})\text{butyl})\text{-1H-indole-2-carboxamide (1)} \) was prepared as previously described [30]. Compound 1 (220 mg, 0.5 mmol) was dissolved in chloroform and cooled to \(-78 \degree C\). Boron tribromide (375 mg, 1.5 mmol) was added and the temperature was slowly allowed to increase to room temperature with continued stirring, for 8 h. The reaction mixture was quenched in ice-cold water, neutralized with ammonium hydroxide solution (10%) to pH 9.0 and extracted with chloroform (4 × 50 mL). The organic layers were combined, dried, concentrated and purified using flash chromatography (40% acetone/chloroform as eluent) to provide 138 mg (65%) of the product 2 as a white solid. m.p. 148–149 \degree C. \(^1H\)-NMR (400 MHz, CDCl\(_3\)) \( \delta \) 9.20 (s, 1H), 7.64 (d, \( J = 8.0 \) Hz, 1H), 7.44 (d, \( J = 7.7 \) Hz, 1H), 7.33–7.21 (m, 2H), 7.18–7.06 (m, 2H), 7.00 (d, \( J = 7.4 \) Hz, 1H), 6.79 (dd, \( J = 17.8, 9.6 \) Hz, 2H), 6.44 (s, 1H), 3.51 (d, \( J = 19.2 \) Hz, 4H), 2.92 (s, 3H), 2.63 (s, 3H), 2.49 (s, 2H), 1.70 (s, 4H). \(^{13}C\)-NMR (101 MHz, CDCl\(_3\)) \( \delta \) 161.55, 147.84, 139.99, 136.13, 130.88, 127.62, 126.68, 124.49, 116.55, 147.84, 139.99, 136.13, 130.88, 127.62, 126.68, 124.49, 116.55, 147.84, 139.99, 136.13, 130.88, 127.62, 126.68, 124.49.
121.77, 120.60, 119.99, 119.46, 119.04, 111.80, 101.65, 57.98, 53.67, 52.32, 39.68, 27.58, 24.29. HRMS (TOF MS EI+) calculated for C_{23}H_{28}ClN_{4}O_{2} [M + H^{+}] 427.1895, found 427.1897.

3.2. Binding Affinity of 1 to other Neuroreceptors

Off target screening data were obtained through the NIDA Addiction Treatment Discovery Program contract (ADA151001) with Oregon Health & Science University.

3.3. Radiosynthesis

No-carrier-added (NCA) [^{11}C]iodomethane ([^{11}C]CH3I) was produced from cyclotron-produced [^{11}C]carbon dioxide via reduction to [^{11}C]methane followed by vapor-phase iodination [52]. Thus, cyclotron-produced [^{11}C]carbon dioxide (~65–87 GBq) was delivered to a PETtrace MeI process module (GE Medical Systems; Severna Park, MD) through stainless tubing (OD 1/8 in, ID 1/16 in) over 2 min, trapped on molecular sieve (13X), and reduced to [^{11}C]methane over nickel at 360 °C. [^{11}C]Methane was then recirculated over iodine at 720 °C to generate [^{11}C]CH3I, which was trapped on Porapak Q held in the recirculation path. [^{11}C]CH3I was swept with a stream of He gas (17 mL/min) into a stainless-steel loop [37] pre-loaded with a mixture of precursor 2 (1.5–1.9 μmol) and nBu4NOH (1 M in MeOH, 2.1–3.0 μmol) dissolved in DMF (80 μL). When radioactivity reached a maximum in the loop (determined by a proximal radiation detector) the He gas flow was stopped and the reaction allowed to proceed for 5 min at room temperature. The contents of the loop were then injected onto a semi-preparative HPLC column (Luna C18, 10 × 250 mm, 10 μm; Phenomenex, Torrance CA) eluted with MeCN:25 mM aqueous HCO3-NH4 (52:48, v/v) at 6 mL/min, with eluate monitored for radioactivity and absorbance at 254 nm. The radioactive fraction (tR = 10–12 min) corresponding to the desired product was collected in a flask, evaporated to dryness in vacuo, redissolved in 10% ethanol/saline (10 mL, v/v), and passed through a sterile 0.22 μm filter (Milllex-MP; Millipore, Burlington, MA, USA) into a sterile vial. For rodent PET studies, the procedure was performed without terminal filtration. Radiochemical and chemical purities were measured with analytical HPLC on a Luna C18 column, (4.6 × 250 mm, 10 μm; Phenomenex) eluted with MeCN:25 mM aqueous HCO3-NH4 (60:40, v/v) at 2 mL/min with eluate monitored for radioactivity and absorbance at 254 nm. The identity of [^{11}C]I was confirmed by observing HPLC co-mobility with 1, and with LC-MS analysis of the associated carrier.

3.4. Lipophilicity (logD_{7.4}) Measurements and Stability in Aqueous Buffer

The value for the distribution coefficient (logD_{7.4}) of [^{11}C]I between 1-octanol and sodium phosphate buffer (0.15 M, pH 7.4) was determined with a technique described previously [53]. The radioligand in ethanol/saline was placed in sodium phosphate buffer (0.15 M, pH 7.4) for the duration of the experiment followed by the determination of its radiochemical purity to obtain information on its stability in buffer. [^{11}C]I (293 MBq in 600 μL) was added to sodium phosphate buffer (0.15 M, pH 7.4; 7.0 mL) and mixed well. Aliquots (1.0 mL) were distributed to eight borosilicate disposable culture tubes (13 × 100 mm). Six tubes each contained 1-octanol (1.0 mL), and two tubes (without octanol) served for determining the stability of [^{11}C]I and adsorption to the walls of the tube by incubation for the duration of the experiment. Radioactivities from six tubes were extracted with 1-octanol. Extraction was performed by vortexing the tubes with their content for 1 min. The tubes were centrifuged for 1 min. The organic and the aqueous phases were separated. Each phase was then sampled 50 μL and 200 μL respectively and counted separately in a well-type γ-counter (model 1480 Wizard; Perkin-Elmer) with an electronic window set between 360 and 1800 keV. The remaining two tubes, contained the radioactivity in buffer and served as stability measures for the radioligand. Radioactivity in the aqueous phases (200 μL) resulted in counting error of 0.3 ± 0.03% (n = 6) at one standard deviation. The radiochemical composition of the aqueous buffer after extraction with 1-octanol was determined with HPLC on an X-Terra C18 column (10 μm, 7.8 × 300 mm; Waters Corp., Milford, MA, USA) eluted with MeOH:H2O:Et3N (80:20:0.1 v/v/v) at 4.0 mL/min. The HPLC
system consisted of Beckman Gold (Beckman Coulter, Inc.; Fullerton, CA, USA) analytic pumps equipped with an in-line photodiode-array detector and a flow-through NaI scintillation detector-rate meter (Bioscan, Washington, DC, USA). The resulting radiochromatograms provided correction factors for the $\gamma$-counter counts to determine parent radioactivity only (corrected radioactivity). Data from the radioanalyses were collected and stored with Bio-Chrome Lite software (Bioscan) and analyzed after decay correction of the radiochromatograms. $\log D_{7.4}$ was calculated according to the following formula:

$$\log D_{7.4} = \log \left( \frac{\text{cpm organic phase}}{\text{corrected cpm aqueous phase}} \right)$$

(1)

3.5. Tissue Stability

The stability of $[^{11}\text{C}]1$ was evaluated in rat whole blood, human and rat plasmas, and rat, monkey and human brain homogenates. These tissues were stored frozen at $-70^\circ\text{C}$ but thawed on the day of analysis. $[^{11}\text{C}]1$ (~370 kBq/10.0 µL) was added to thawed tissues (500 µL), mixed well and incubated at 37 °C for 30 min. Plasma analysis was performed as reported previously [54]. The stability of $[^{11}\text{C}]1$ was expressed as the tissue radiochromatographic composition divided by the radiochemical purity of the radioligand.

3.6. Plasma Free Fraction

The plasma free fraction ($f_p$) of $[^{11}\text{C}]1$ was measured with ultrafiltration through membrane filters (Centrifree; Millipore; Burlington MA), as previously described [55]. Briefly, $[^{11}\text{C}]1$ (925 kBq, ~23 µL) was added to the plasma (1000 µL). The mixture was incubated at room temperature for 10 min and then processed as described previously. The ultrafiltration components that contained high radioactivity were allowed to decay to within the optimal range of the $\gamma$-counter before they were counted. Quantification of the ultrafiltrates was performed gravimetrically.

3.7. Cell Uptake Percentage

Blood hematocrit (Hct) was determined using heparinized capillary tubes (12 × 40 mm) to sample blood drawn after the injection of the vehicle, and immediately before injection of $[^{11}\text{C}]1$. The capillary tubes were then centrifuged, and Hct determined using a StatSpin® CritSpin™ Microhematocrit system (Los Angeles, CA, USA). Aliquots of anticoagulated rat blood (250 µL) were placed in three Eppendorf tubes (1.5 mL). $[^{11}\text{C}]1$ (18.5 kBq) was added to each tube and incubated at 37 °C for 30 min. Then whole blood (50 µL) was removed from each tube and counted in the $\gamma$-counter. The tubes were then centrifuged before removing plasma (50 µL) for $\gamma$-counting. The relative cellular blood (RBC, WBC and platelets) partitioning of $[^{11}\text{C}]1$ was then calculated as:

$$\%\text{Cell} = \frac{C_{\text{whole blood}} - C_{\text{plasma}} \times (1 - \text{Hct})}{C_{\text{whole blood}}}$$

(2)

where $C_{\text{whole blood}}$ is the concentration of radioactivity in whole blood (cpm/mL), $C_{\text{plasma}}$ is the concentration of radioactivity in plasma (cpm/mL), and Hct is the hematocrit.

3.8. Rat Ex Vivo Measurements

$[^{11}\text{C}]1$, in 10% ethanol-saline solution, was injected intravenously through the penile vein in two anesthetized male Sprague-Dawley rats. One rat served as baseline and the other was pre-treated at about 10 min before $[^{11}\text{C}]1$ injection with tariquidar (16 mg/kg; 2.1 mL). Rats were anesthetized with 1.5% isoflurane in oxygen. Thirty minutes after injection of $[^{11}\text{C}]1$ (~74 MBq) a large anticoagulated (heparin) blood sample was drawn. The rats were then immediately sacrificed by decapitation, and their cortices, cerebella, and striata were excised. Each of the brain tissues was placed in MeCN (1 mL) and counted in a $\gamma$-counter. Each brain tissue along with added 1 (50 µg) was then homogenized with
a hand-held tissue Tearor (model 985-370; BioSpec Products Inc., Bartlesville OK). Water (500 µL) was then added and the tissues were further homogenized and counted in the γ-counter for calculating recoveries into MeCN. The homogenates were centrifuged at 10,000 × g for 1 min. The clear supernatant liquids were injected onto a C18 column (X-terra, 10 µm, 7.8 × 300 mm; Waters Corp., Milford, MA, USA) eluted with MeOH:H₂O:Et₃N (78.5:21.5:0.1 v/v/v) at 4.0 mL/min. After separating plasma from blood cells, plasma samples (200 µL) were counted in γ-counter and plasma aliquots (450 µL) were each placed in MeCN (720 µL) along with carrier 1 (5 µg) for deproteinization. After mixing the samples well, H₂O (100 µL) was added. The samples were further mixed well, counted in a γ-counter, and centrifuged at 10,000 × g for 1 min. Supernatants were injected onto the radio-HPLC and analyzed under the above conditions. All precipitates were counted in the γ-counter for calculating recoveries in the supernatants that were injected onto the HPLC.

An untreated rat served as a control for in vitro experiments. Anticoagulated blood, plasma, and frontal brain were harvested. The brain (1.6 g) was homogenized in cold saline. After adding [¹¹C]I to the whole blood, plasma and brain homogenate, the tissues were incubated at 37 °C for 1.0 h. In vitro whole blood (200 µL) was placed in water (300 µL) to lyse open all cells. Then an aliquot (450 µL) was removed and placed in MeCN (720 µL). Tissue samples were then processed as detailed above and subjected to radio-HPLC analysis.

3.9. PET Imaging

PET imaging experiments were performed in accordance with the Guide for Care and Use of Laboratory Animals [56] and were approved by the National Institute of Mental Health Animal Care and Use Committee. All animals were anesthetized with 1.5% isoflurane. Rat (Sprague-Dawley, male; 346 ± 21 g) scans were acquired with a microPET Focus 220 scanner (Siemens Medical Solutions, Knoxville, TN, USA) for a duration of 90 min. [¹¹C]I (~23.8 ± 0.9 MBq) was injected intravenously (i.v.) through a tail vein catheter. In some rats, tariquidar (16 mg/kg, i.v.) was administered at 15 min before radioligand injection. In some other rats, drug challenge agents (BP897, 0.5 mg/kg, i.v., or spiperone, 1.0 mg/kg, i.v.) were administered at 10 min before radioligand injection for preblocking experiments or 15 min after radioligand injection for displacement experiments. For experiments in mice (wild type and P-gp/BCRP knock-out; male; Taconic FVB.129P2-Abcb1atm1Bor-Abcb1btm1Bor-Abcg2tm1AhsN7; 27 ± 1.1 g), scans were acquired with a microPET Focus 120 camera for a duration of 90 min. [¹¹C]I (~9.9 ± 1.5 MBq) was injected through a tail vein catheter. Monkey (male rhesus macaque, 9.9 kg) experiments were acquired using microPET Focus 220 (Siemens Medical Solutions, Knoxville TN) for a duration of 90 min. A bolus [¹¹C]I (~229 MBq) was injected intravenously at baseline. In the same monkey, a second PET experiment was performed 3 h later, in which tariquidar (8 mg/kg, i.v.) was administered at 10 min before injection of [¹¹C]I (~329 MBq).

Images were reconstructed using Fourier rebinning followed by 2D OSEM with attenuation correction for rats and monkey and without attenuation correction for mice. Scatter correction was applied only for monkey. Volume of interests were delineated manually for rats and mice, and with a co-registered MRI template for monkey. All radioactivity was decay-corrected and expressed as standardized uptake value (SUV) which is radioactivity concentration corrected for subject weight and administered dose. Time activity curves in SUV were obtained and compared between conditions. The PET data analysis was performed using PMOD.

4. Conclusions

[¹¹C]I was labeled by ¹¹C-methylation of its desmethyl precursor (2) in high yield and molar activity. In vivo evaluation with PET showed that [¹¹C]I was an avid substrate of efflux transporters and lacked D₃R-specific signal in rodents and monkey. Binding to off-target D₂R appeared absent in rat striatum, thereby indicating that D₂R affinity (Kᵢ = 53 nM) is adequately low. Candidate PET radioligands with absence of efflux transporter behavior and with even higher D₃R affinity are likely required for successful PET imaging of D₃R.
Author Contributions: V.W.P., A.H.N. and R.B.I. conceived and supervised the project; V.W.P., S.L., J.-S.L. and S.S.Z. designed the experiments; S.L., J.-S.L., C.L.M., R.L.G., M.F., G.L.T., S.S.Z. and A.B.S. performed the experiments; V.W.P., S.L., J.-S.L. and S.S.Z. analyzed the data; S.L., V.W.P. and A.H.N. wrote and revised the paper; all coauthors reviewed and commented on the manuscript drafts and revisions.

Funding: This work was supported by the Intramural Research Program of the National Institutes of Health (NIMH, project numbers ZIA-MH002793 and ZIA-MH002795; NIDA, project number ZIA-DA000424).

Acknowledgments: The authors are grateful to the NIH Clinical PET Center (Chief P. Herscovitch) for the cyclotron supply of carbon-11 and PMOD Technologies for providing the image analysis software.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Maramai, S.; Gemma, S.; Brogi, S.; Campiani, G.; Butini, S.; Stark, H.; Brindisi, M. Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases. Front. Neurosci. 2016, 10, 451. [CrossRef] [PubMed]
2. Schwartz, J.C.; Levesque, D.; Martres, M.P.; Sokoloff, P. Dopamine-D3 receptor–basic and clinical aspects. Clin. Neuropharmacol. 1993, 16, 295–314. [CrossRef] [PubMed]
3. Levant, B. The D3 dopamine receptor: Neurobiology and potential clinical relevance. Pharmacol. Rev. 1997, 49, 231–252. [PubMed]
4. Sokoloff, P.; Giros, B.; Martres, M.P.; Andrieux, M.; Besancon, R.; Pilon, C.; Bouthenet, M.L.; Souil, E.; Schwartz, J.C. Localization and function of the D3 dopamine receptor. Arzneim. Forsch. 1992, 42, 224–230.
5. Heidbreder, C.A.; Newman, A.H. Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann. N. Y. Acad. Sci. 2010, 1187, 4–34. [CrossRef] [PubMed]
6. Prieto, G.A. Abnormalities of dopamine D3 receptor signaling in the diseased brain. J. Cent. Nerv. Syst. Dis. 2017, 9, 1–8. [CrossRef] [PubMed]
7. Richtand, N.M.; Woods, S.C.; Berger, S.P.; Strakowski, S.M. D3 dopamine receptor, behavioral sensitization, and psychosis. Neurosci. Biobehav. Rev. 2001, 25, 427–443. [CrossRef]
8. Leggio, G.M.; Salomone, S.; Bucolo, C.; Platania, C.; Micale, V.; Caraci, F.; Drag, F. Dopamine D3 receptor as a new pharmacological target for the treatment of depression. Eur. J. Pharmacol. 2013, 719, 25–33. [CrossRef] [PubMed]
9. Paterson, N.E.; Voci, F.; Sevak, R.J.; Wagreich, E.; London, E.D. Dopamine D3 receptors as a therapeutic target for methamphetamine dependence. Am. J. Drug Alcohol Abuse 2014, 40, 1–9. [CrossRef] [PubMed]
10. Keck, T.M.; John, W.S.; Czoty, P.W.; Nader, M.A.; Newman, A.H. Identifying medication targets for psychostimulant addiction: Unraveling the dopamine D3 receptor hypothesis. J. Med. Chem. 2015, 58, 5361–5380. [CrossRef] [PubMed]
11. Newman, A.H.; Blaylock, B.L.; Nader, M.A.; Bergman, J.; Sibley, D.R.; Skolnick, P. Medication discovery for addiction: Translating the dopamine D3 receptor hypothesis. Biochem. Pharmacol. 2012, 84, 882–890. [CrossRef] [PubMed]
12. Phelps, M.E.; Mazziotto, J.C. Positron emission tomography–human brain function and biochemistry. Science 1985, 228, 799–809. [CrossRef] [PubMed]
13. Ametamey, S.M.; Honer, M.; Schubiger, P.A. Molecular imaging with PET. Chem. Rev. 2008, 108, 1501–1516. [CrossRef] [PubMed]
14. Hargreaves, R.J. The role of molecular imaging in drug discovery and development. Clin. Pharmacol. Ther. 2008, 83, 349–353. [CrossRef] [PubMed]
15. Heiss, W.D.; Herholz, K. Brain receptor imaging. J. Nucl. Med. 2006, 47, 302–312. [PubMed]
16. Piel, M.; Vernaleken, I.; Rosch, F. Positron emission tomography in CNS drug discovery and drug monitoring. J. Med. Chem. 2014, 57, 9232–9258. [CrossRef] [PubMed]
17. Mach, R.H.; Luedtke, R.R. Challenges in the development of dopamine D2- and D3-selective radiotracers for PET imaging studies. J. Label. Compd. Radiopharm. 2018, 61, 291–298. [CrossRef] [PubMed]
18. Luedtke, R.R.; Mach, R.H. Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. Curr. Pharm. Des. 2003, 9, 643–671. [CrossRef]
19. Parsons, B.; Stanley, M.; Javitch, J. Differential visualization of dopamine-D2 and dopamine-D3 receptors in rat-brain. *Eur. J. Pharmacol.* **1993**, *234*, 269–272. [CrossRef] [PubMed]

20. Sun, J.; Cairns, N.J.; Perlmutter, J.S.; Mach, R.H.; Xu, J. Regulation of dopamine D3 receptor in the striatal regions and substantia nigra in diffuse lewy body disease. *Neuroscience* **2013**, *248*, 112–126. [CrossRef] [PubMed]

21. Gallezot, J.D.; Beaver, J.D.; Gunn, R.N.; Nabulsi, N.; Weinheimer, D.; Singhal, T.; Slifstein, M.; Fowles, K.; Ding, Y.S.; Huang, Y.; et al. Affinity and selectivity of 11C-((+)-PHNO for the D2 and D3 receptors in the rhesus monkey brain in vivo. *Synapse* **2012**, *66*, 489–500. [CrossRef] [PubMed]

22. Xu, J.B.; Hassanzadeh, B.; Chu, W.H.; Tu, Z.D.; Jones, L.A.; Luedtke, R.R.; Perlmutter, J.S.; Mintun, M.A.; Mach, R.H. 3H4-(dimethylamino)-n-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)benzamide: A selective radioligand for dopamine D3 receptors. II. Quantitative analysis of dopamine D3 and D2 receptor density ratio in the caudate-putamen. *Synapse* **2010**, *64*, 449–459. [CrossRef] [PubMed]

23. Wilson, A.A.; McCormick, P.; Kapur, S.; Willeit, M.; Garcia, A.; Hussey, D.; Houle, S.; Seeman, P.; Ginovart, N. Radiosynthesis and evaluation of 11C-((+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][4,oxazin-9-ol] as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. *J. Med. Chem.* **2005**, *48*, 4153–4160. [CrossRef] [PubMed]

24. Sovago, J.; Farde, L.; Halldin, C.; Langer, O.; Laszlovszky, I.; Kiss, B.; Gulyas, B. Positron emission tomographic evaluation of the putative dopamine D2 receptor ligand, [11C]RGH-1756 in the monkey brain. *Neurosci. Int.* **2004**, *45*, 617–669. [CrossRef] [PubMed]

25. Mach, R.H.; Tu, Z.D.; Xu, J.B.; Li, S.H.; Jones, L.A.; Taylor, M.; Derdeyn, C.P.; Perlmutter, J.S.; Mintun, M.A. Endogenous dopamine (DA) competes with the binding of a radiolabeled D3 receptor partial agonist in vivo: A positron emission tomography study. *Synapse* **2011**, *65*, 724–732. [CrossRef] [PubMed]

26. Kuhnast, B.; Valette, H.; Besret, L.; Demphel, S.; Coulon, C.; Ottaviani, M.; Guillermier, M.; Botlaender, M.; Dolle, F. Synthesis and radiolabeling of N-[4-[4-(11C)ethoxyphenyl]piperazin-1-yl]butyl]benzo[bthiophene-2-carboxamide—A potential radiotracer for D3 receptor imaging with PET. *Nucl. Med. Biol.* **2006**, *33*, 785–795. [CrossRef] [PubMed]

27. Stewart, M.N.; Shao, X.; Desmond, T.J.; Forrest, T.J.; Arteaga, J.; Stauff, J.; Scott, P.J.H. Synthesis and pre-clinical evaluation of a potential radiotracer for PET imaging of the dopamine D3 receptor. *MedChemComm* **2018**, *9*, 13151–13161. [CrossRef] [PubMed]

28. Prante, O.; Maschauer, S.; Banerjee, A. Radioligands for the dopamine receptor subtypes. *J. Label. Compd. Radiopharm.* **2013**, *56*, 130–148. [CrossRef] [PubMed]

29. Payer, D.; Balasubramaniam, G.; Boileau, I. What is the role of the D3 receptor in addiction? A mini review of PET studies with [11C]-((+)-PHNO. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2014**, *52*, 4–8. [CrossRef] [PubMed]

30. Boateng, C.A.; Bakare, O.M.; Zhan, J.; Banala, A.K.; Burzynski, C.; Pommier, E.; Keck, T.M.; Donthamsetti, P.; Javitch, J.A.; Rais, R.; et al. High affinity dopamine D3 receptor (D3R)-selective antagonists attenuate heroin self-administration in wild-type but not D3R knockout mice. *J. Med. Chem.* **2015**, *58*, 6195–6213. [CrossRef] [PubMed]

31. Newman, A.H.; Beuming, T.; Banala, A.K.; Donthamsett, P.; Pongetti, K.; LaBounty, A.; Levy, B.; Cao, J.J.; Michino, M.; Luedtke, R.R.; et al. Molecular determinants of selectivity and efficacy of the dopamine D3 receptor. *J. Med. Chem.* **2012**, *55*, 6689–6699. [CrossRef] [PubMed]

32. Chien, E.Y.T.; Liu, W.; Zhao, Q.A.; Katritch, V.; Han, G.W.; Hanson, M.A.; Shi, L.; Newman, A.H.; Javitch, J.A.; Cherezov, V.; et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. *Science* **2010**, *330*, 1091–1095. [CrossRef] [PubMed]

33. Michino, M.; Donthamsetti, P.; Beuming, T.; Banala, A.; Duan, L.H.; Roux, T.; Han, Y.; Tranquet, E.; Newman, A.H.; Javitch, J.A.; et al. A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors. *Mol. Pharmacol.* **2013**, *84*, 854–864. [CrossRef] [PubMed]

34. Wager, T.T.; Chandrasekaran, R.Y.; Hou, X.J.; Troutman, M.D.; Verhoest, P.R.; Villalobos, A.; Will, Y. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. *ACS Chem. Neurosci.* **2010**, *1*, 420–434. [CrossRef] [PubMed]

35. Wager, T.T.; Hou, X.J.; Verhoest, P.R.; Villalobos, A. Central nervous system multiparameter optimization desirability: Application in drug discovery. *ACS Chem. Neurosci.* **2016**, *7*, 767–775. [CrossRef] [PubMed]
36. Wager, T.T.; Hou, X.J.; Verhøest, P.R.; Villalobos, A. Moving beyond rules: The development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem. Neurosci. 2010, 1, 435–449. [CrossRef] [PubMed]

37. Wilson, A.A.; Garcia, A.; Jin, L.; Houle, S. Radiotracer synthesis from $^{[11]}$C]iodomethane: A remarkably simple captive solvent method. Nucl. Med. Biol. 2000, 27, 529–532. [CrossRef]

38. Pike, VW. Considerations in the development of reversibly binding PET radioligands for brain imaging. Curr. Med. Chem. 2016, 23, 1818–1869. [CrossRef] [PubMed]

39. Terry, G.E.; Liow, J.S.; Zoghbi, S.S.; Hirvonen, J.; Farris, A.G.; Lerner, A.; Tauscher, J.T.; Schaus, J.M.; Phebus, L.; Felder, C.C.; et al. Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand. Neuroimage 2009, 48, 362–370. [CrossRef] [PubMed]

40. Roe, M.; Folkes, A.; Ashworth, P.; Brumwell, J.; Chima, L.; Hunjan, S.; Pretswell, I.; Dangerfield, W.; Ryder, H.; Charlton, P. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg. Med. Chem. Lett. 1999, 9, 595–600. [CrossRef]

41. Froklage, F.E.; Syvaanen, S.; Hendrikse, N.H.; Huismans, M.C.; Molthoff, C.F.; Tagaga, Y.; Reijneveld, J.C.; Heimans, J.J.; Lammertsma, A.A.; Eriksson, J.; et al. $^{11}$Cfluromazenil brain uptake is influenced by the blood-brain barrier efflux transporter P-glycoprotein. EJNMMI Res. 2012, 2, 12. [CrossRef] [PubMed]

42. Kannan, P.; Telu, S.; Shukla, S.; Ambudkar, S.V.; Pike, V.W.; Halldin, C.; Gottessman, M.M.; Innis, R.B.; Hall, M.D. The “specific” P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem. Neurosci. 2011, 2, 82–89. [CrossRef] [PubMed]

43. Narendran, R.; Slištein, M.; Guillin, O.; Hwang, Y.Y.; Hwang, D.R.; Scher, E.; Reeder, S.; Rabiner, E.; Laruelle, M. Dopamine (D$_2$)/D$_3$ receptor agonist positron emission tomography radiotracer $^{[11]}$C$^-$PHNO is a D$_3$ receptor preferring agonist in vivo. Synapse 2006, 60, 485–495. [CrossRef] [PubMed]

44. Urwyler, S.; Coward, D. Binding of $^3$H$^-$spiperone and $^3$H$^-$(-)-sulpiride to dopamine D$_2$ receptors in rat striatal membranes—methodological considerations and demonstration of the identical nature of the binding-sites for the two ligands. Naunyn Schmiedebergs Arch. Pharmacol. 1987, 335, 115–122. [CrossRef] [PubMed]

45. Dambaut, P.; Cantineau, R.; Lemaire, C.; Plenevaux, A.; Christiaens, L.; Guillaume, M. 2- and 4[18F]fluorotripapride, two specific D$_2$-receptor ligands for positron emission tomography: NCA syntheses and animal studies. Appl. Radiat. Isot. 1992, 43, 1265–1274. [CrossRef]

46. Boy, C.; Klimke, A.; Holschbach, M.; Herzog, H.; Muhlniespen, H.; Kops, E.R.; Sonnenberg, F.; Gaebel, W.; Stocklin, G.; Markstein, R.; et al. Imaging dopamine D$_4$ receptors in the living primate brain: A positron emission tomography study using the novel D$_1$/D$_4$ antagonist $^{[11]}$CSDZ GLC 756. Synapse 1998, 30, 341–350. [CrossRef] [PubMed]

47. Leggio, G.M.; Bucolo, C.; Platania, C.B.M.; Salomone, S.; Drago, F. Current drug treatments targeting dopamine D$_3$ receptor. Pharmacol. Ther. 2016, 165, 164–177. [CrossRef] [PubMed]

48. Micheli, F. Recent advances in the development of dopamine D$_3$ receptor antagonists: A medicinal chemistry perspective. ChemMedChem 2011, 6, 1152–1162. [CrossRef] [PubMed]

49. Rabiner, E.A.; Slištein, M.; Nobrega, J.; Plisson, C.; Huiban, M.; Raymond, R.; Diwan, M.; Wilson, A.A.; McCormick, P.; Gentile, G.; et al. In vivo quantification of regional dopamine-D$_3$ receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice. Synapse 2009, 63, 782–793. [CrossRef] [PubMed]

50. Kumar, V.; Bonifazi, A.; Ellenberger, M.P.; Keck, T.M.; Pommier, E.; Rais, R.; Slusser, B.S.; Gardner, E.; You, Z.B.; Xi, Z.X.; et al. Highly selective dopamine D$_3$ receptor (D$_3$R) antagonists and partial agonists based on etclopride and the D$_3$R crystal structure: New leads for opioid dependence treatment. J. Med. Chem. 2016, 59, 7634–7650. [CrossRef] [PubMed]

51. Sovago, J.; Farde, L.; Halldin, C.; Schukin, E.; Schou, M.; Laszlovszky, I.; Kiss, B.; Gulyas, B. Lack of effect of reserpine-induced dopamine depletion on the binding of the dopamine-D$_3$ selective radioligand, $^{[11]}$C]RGH-1756. Brain Res. Bull. 2005, 67, 219–224. [CrossRef] [PubMed]

52. Larsen, P.; Ulin, J.; Dahlstrom, K.; Jensen, M. Synthesis of $^{[11]}$Ciodomethane by iodination of $^{[11]}$Cmethylene. Appl. Radiat. Isot. 1997, 48, 153–157. [CrossRef]

53. Zoghbi, S.S.; Anderson, K.B.; Jenko, K.J.; Luckenbaugh, D.A.; Innis, R.B.; Pike, V.W. On quantitative relationships between drug-like compound lipophilicity and plasma free fraction in monkey and human. J. Pharm. Sci. 2012, 101, 1028–1039. [CrossRef] [PubMed]
54. Zoghbi, S.S.; Shetty, H.U.; Ichise, M.; Fujita, M.; Imaizumi, M.; Liow, J.S.; Shah, J.; Musachio, J.L.; Pike, V.W.; Innis, R.B. PET imaging of the dopamine transporter with \(^{18}\text{F}\)-FECNT: A polar radiometabolite confounds brain radioligand measurements. *J. Nucl. Med.* 2006, 47, 520–527. [PubMed]

55. Gandelman, M.S.; Baldwin, R.M.; Zoghbi, S.S.; Zea-Ponce, Y.; Innis, R.B. Evaluation of ultrafiltration for the free-fraction determination of single-photon emission computed-tomography (SPECT) radiotracers—\(\beta\)-CIT, IBF and iomazenil. *J. Pharm. Sci.* 1994, 83, 1014–1019. [CrossRef] [PubMed]

56. National Research Council (U.S.); Committee for the Update of the Guide for the Care and Use of Laboratory Animals; Institute for Laboratory Animal Research (U.S.). *Guide for the Care and Use of Laboratory Animals*, 8th ed.; National Academies Press: Washington, DC, USA, 2011.